Tenacia获Rap-219在大中华区独家开发和商业化权益

美股速递
Mar 09

Rapport Therapeutics, Inc. 宣布,Tenacia公司已获得其候选药物Rap-219在大中华区(包括中国大陆、香港、澳门和台湾)的独家开发和商业化权利。此次授权合作将加速该疗法在亚太市场的布局,为当地患者提供新的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10